Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

H.C. Wainwright raised the firm’s price target on Bicara Therapeutics (BCAX) to $45 from $42 and keeps a Buy rating on the shares after the ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.